Kisqali on PBS, very few will get it.
those of us who were waiting to get Ibrance or Kisqali on PBS we will not get either. Only newly the diagnosed who have NOT had an Aromatose drug. ( there would be very few of them ) BCNA failed t...
Forum Discussion
WendyLou,
This is the email of received and in fairness to BCNA - I think it makes sense.
I read the PBS listing like you did - I explained why.
It adresses Palbociclib and finds Ribociclib a comparable alternative in the last paragraph.
I knew that the govermenrt did not reach a deal with Pfizer on Palbociclib.
IMO the PBS phraseology is skewed. I was not aware that men have been included and are happy to hear it - I think we are still missing some big groups from the listing - so yes progress, but a lot of work left to do.
That is really all I have to say.
This is the email of received and in fairness to BCNA - I think it makes sense.
I read the PBS listing like you did - I explained why.
Dear...
I wanted to reach out to you to respond to one of the posts you responded to around eligibility criteria for PBS ribociclib.
I followed up today with Novartis seeking clarification as to whether there was a restriction for women who had received and aromatase inhibitor in the adjuvant setting. The lead medical advisor advised me today that there is no restriction on women who progress to develop metastatic disease following a diagnosis from early breast cancer even if they did receive an AI in the past for their early stage disease. Obviously this needs to be a one on one discussion between a doctor and individual women as to what the best treatment is and past treatment will come into those discussions.
I am concerned that your post about concerns for all those women who have received an AI in the post not being able to access this drug should they go onto progress to metastatic disease sends a false message and is causing angst amongst the online community.
Is it possible that you could repost to advise the online community that BCNA has been able to clarify this for you and reassure women who are worried?
Happy to chat to you over the phone if you need further clarification.
Kind regards
Danielle
I corrected my post.
This is the PBAC recommendationIt adresses Palbociclib and finds Ribociclib a comparable alternative in the last paragraph.
I knew that the govermenrt did not reach a deal with Pfizer on Palbociclib.
IMO the PBS phraseology is skewed. I was not aware that men have been included and are happy to hear it - I think we are still missing some big groups from the listing - so yes progress, but a lot of work left to do.
That is really all I have to say.